Abstract
e15122 Background: Currently, there is no standard treatment after progression in the first-line therapy with gemcitabine-based regimens for pancreatic and biliary tract carcinomas. Methods: We ret...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
